Reversing or slowing biological age — epigenetic reprogramming, senolytics, gene therapy, partial reprogramming.
Tohoku University / Renascience (Japan) – First human trial (n=20, 4 months) of a PAI-1 inhibitor in healthy older adults. Results: ↓biological age 2-3 years (epigenetic clock), improved immune and stem cell function, reduced inflammatory markers. No serious adverse events. XPRIZE Healthspan semi‑finalist.